Review Article Abstract Introduction Retatrutide for Treatment of Obesity Retatrutide for Treatment of Type 2 Diabetes Effects of Retatrutide on Cardiovascular Risk Factors Safety of Retatrutide Effect of Retatrutide on Heart Rate Advantages of Retatrutide Limitations of Retatrutide Conclusions and Current Needs References Retatrutide for Treatment of Obesity Retatrutide, in different subcutaneous doses of 1, 4, 8 and 12mg and escalation schedules, was evaluated for treatment of obesity in a phase 2, randomized, placebo-controlled, double-blind trial of 48 week-duration in the USA (Table 1) [3]
La retatrutida activa GLP-1R + GIPR + GcgR
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent
Results based on a January 2026 analysis of 14,203 Noom GLP-1Rx Program members who actively logged weight over a 40 week period
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
